Krishna Komanduri, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Avacta Therapeutics
    Topic: 
    Oncology drug development
    Date added: 
    04/21/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Novartis
    Topic: 
    Cellular therapy
    Date added: 
    04/21/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Iovance
    Topic: 
    Cellular therapy
    Date added: 
    04/21/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Optum Health
    Topic: 
    Oncology treatment pathways
    Date added: 
    04/21/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    CRISPR Therapeutics
    Topic: 
    Cellular therapy
    Date added: 
    04/21/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Cargo Therapeutics
    Topic: 
    Cellular Therapy
    Date added: 
    04/21/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Janssen
    Topic: 
    Cellular Therapy
    Date added: 
    04/21/2023
  • Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Incyte
    Topic: 
    Graft vs. Host Disease
    Date added: 
    04/21/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Roche
    Topic: 
    T cell engager therapy
    Date added: 
    04/21/2023
Return to 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology